Valion Bio, Inc. (VBIO) earnings
Quarterly results of Valion Bio, Inc. as filed with the SEC: revenue, net income and earnings per share for each of the last 8 quarters, the latest results release and when the next one is expected.
Latest quarter: Q2 FY2026
In Q2 FY2026 (ended June 30, 2026) Valion Bio, Inc. reported revenue of - and a net loss of $7.1M.
Diluted earnings per share were -$2.17.
Quarter by quarter
| Quarter | Revenue | vs year ago | Net income | EPS |
|---|---|---|---|---|
| Q2 FY2026 | - | - | -$7.1M | -$2.17 |
| Q1 FY2026 | - | - | -$6.2M | -$2.23 |
| Q4 FY2025 | - | - | -$2.8M | - |
| Q3 FY2025 | $146K | +15.9% | -$2.6M | -$1.97 |
| Q2 FY2025 | $86K | - | -$1.9M | -$2.19 |
| Q1 FY2025 | $70K | - | -$1.5M | -$2.52 |
| Q4 FY2024 | $180K | - | -$1.5M | - |
| Q3 FY2024 | $126K | - | -$1.4M | -$0.23 |
Results filings
- Quarterly report 10-Q
Get an email when VBIO reports
Follow VBIO and we email you its next results the day they are filed, with the numbers explained.